Literature DB >> 9472888

Medical and neurological complications of ischemic stroke: experience from the RANTTAS trial. RANTTAS Investigators.

K C Johnston1, J Y Li, P D Lyden, S K Hanson, T E Feasby, R J Adams, R E Faught, E C Haley.   

Abstract

BACKGROUND AND
PURPOSE: Medical and neurological complications after acute ischemic stroke may adversely impact outcome and in some cases may be preventable. Limited data exist regarding the frequency of such complications occurring in the first days after the ictus and the relationship of these complications to outcome. Our objective was to identify the types, severity, and frequency of medical and neurological complications following acute ischemic stroke and to determine their role in mortality and functional outcome.
METHODS: Rates of serious (life-threatening) and nonserious medical and neurological complications and mortality were derived from the placebo limb of the Randomized Trial of Tirilazad Mesylate in Acute Stroke (RANTTAS) database (n=279). Complications were correlated with clinical outcome using logistic regression techniques.
RESULTS: Of all patients, 95% had at least one complication. The most common serious medical complication was pneumonia (5%), and the most common serious neurological complication was new cerebral infarction or extension of the admission infarction (5%). The 3-month mortality was 14%; 51% of these deaths were attributed primarily to medical complications. Outcome was significantly worse in patients with serious medical complications, after adjustment for baseline imbalances, as measured by the Barthel Index (odds ratio [OR], 6.1; 95% confidence interval [CI], 2.5 to 15.1) and by the Glasgow Outcome Scale (OR, 11.6; 95% CI, 4.3 to 30.9). After death was discounted, serious medical complications were associated with severe disability at 3 months as determined by the Glasgow Outcome Scale (OR, 4.4; 95% CI, 1.3 to 14.8).
CONCLUSIONS: Medical complications that follow ischemic stroke not only influence mortality but may influence functional outcome.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9472888     DOI: 10.1161/01.str.29.2.447

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  103 in total

Review 1.  Medical therapy for acute ischemic stroke.

Authors:  L B Goldstein
Journal:  Curr Atheroscler Rep       Date:  2001-07       Impact factor: 5.113

2.  Endoscopy Is Relatively Safe in Patients with Acute Ischemic Stroke and Gastrointestinal Hemorrhage.

Authors:  Mohamed Tausif Siddiqui; Mohammad Bilal; Lakshmi Asritha Gollapudi; Dhruv Mehta; Shifa Umar; Jonathan Barsa; Christopher Nabors; Beth Schorr-Lesnick; Edward Lebovics; Virendra Tewari
Journal:  Dig Dis Sci       Date:  2018-12-05       Impact factor: 3.199

3.  Successful use of Alteplase during cardiopulmonary resuscitation following massive PE in a patient presenting with ischaemic stroke and haemorrhagic transformation.

Authors:  Robert Middleton; Juliane Neumann; Simon Michael Ward
Journal:  BMJ Case Rep       Date:  2014-10-31

4.  Mineralocorticoid-receptor blockade in hypertensive patients during angiotensin-converting enzyme inhibition: effects on left ventricular mass.

Authors:  Robert M Carey; Alexander G Logan
Journal:  Curr Hypertens Rep       Date:  2004-04       Impact factor: 5.369

Review 5.  Osmotic therapy: fact and fiction.

Authors:  Michael N Diringer; Allyson R Zazulia
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

Review 6.  Modulation of the postischemic immune response to improve stroke outcome.

Authors:  Kyra J Becker
Journal:  Stroke       Date:  2010-10       Impact factor: 7.914

7.  Autoimmune responses to brain following stroke.

Authors:  Kyra Becker
Journal:  Transl Stroke Res       Date:  2012-04-05       Impact factor: 6.829

Review 8.  Causes of death among persons who survive an acute ischemic stroke.

Authors:  Shuai Zhang; Wen-Bin He; Nai-Hong Chen
Journal:  Curr Neurol Neurosci Rep       Date:  2014-08       Impact factor: 5.081

9.  C-reactive protein as a prognostic marker after lacunar stroke: levels of inflammatory markers in the treatment of stroke study.

Authors:  Mitchell S V Elkind; Jorge M Luna; Leslie A McClure; Yu Zhang; Christopher S Coffey; Ana Roldan; Oscar H Del Brutto; Edwin Javier Pretell; L Creed Pettigrew; Brett C Meyer; Jorge Tapia; Carole White; Oscar R Benavente
Journal:  Stroke       Date:  2014-02-12       Impact factor: 7.914

10.  Usefulness of serum procalcitonin levels for the early diagnosis of stroke-associated respiratory tract infections.

Authors:  Andreas Hug; Bettina Mürle; Alexander Dalpke; Markus Zorn; Arthur Liesz; Roland Veltkamp
Journal:  Neurocrit Care       Date:  2011-06       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.